Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
7.48
-0.08 (-1.06%)
At close: Oct 10, 2025, 4:00 PM EDT
7.45
-0.03 (-0.40%)
After-hours: Oct 10, 2025, 7:45 PM EDT
Niagen Bioscience Revenue
Niagen Bioscience had revenue of $31.12M in the quarter ending June 30, 2025, with 36.84% growth. This brings the company's revenue in the last twelve months to $116.30M, up 35.89% year-over-year. In the year 2024, Niagen Bioscience had annual revenue of $99.60M with 19.18% growth.
Revenue (ttm)
$116.30M
Revenue Growth
+35.89%
P/S Ratio
4.98
Revenue / Employee
$1,118,298
Employees
104
Market Cap
597.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 99.60M | 16.03M | 19.18% |
Dec 31, 2023 | 83.57M | 11.52M | 15.99% |
Dec 31, 2022 | 72.05M | 4.60M | 6.82% |
Dec 31, 2021 | 67.45M | 8.19M | 13.82% |
Dec 31, 2020 | 59.26M | 12.97M | 28.01% |
Dec 31, 2019 | 46.29M | 14.73M | 46.69% |
Dec 31, 2018 | 31.56M | 10.36M | 48.85% |
Dec 30, 2017 | 21.20M | -463.65K | -2.14% |
Dec 31, 2016 | 21.66M | 3.78M | 21.13% |
Jan 2, 2016 | 17.88M | 2.57M | 16.79% |
Jan 3, 2015 | 15.31M | 5.15M | 50.71% |
Dec 28, 2013 | 10.16M | -1.45M | -12.48% |
Dec 29, 2012 | 11.61M | 3.50M | 43.12% |
Dec 31, 2011 | 8.11M | 546.24K | 7.22% |
Jan 1, 2011 | 7.57M | 1.79M | 30.95% |
Jan 2, 2010 | 5.78M | 1.27M | 28.22% |
Jan 3, 2009 | 4.51M | -247.77K | -5.21% |
Dec 29, 2007 | 4.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NAGE News
- 6 days ago - Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth - Business Wire
- 11 days ago - Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide - Business Wire
- 26 days ago - AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+ - Business Wire
- 2 months ago - Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook - Business Wire
- 2 months ago - Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference - Business Wire
- 2 months ago - Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - Business Wire
- 3 months ago - Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York - Business Wire
- 3 months ago - Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - Business Wire